Definium Therapeutics to Present Results From Three Phase 3 LSD Trials at Psychiatry Congress
Definium Therapeutics (NASDAQ: DFTX) is set to present findings from three positive Phase 3 clinical trials of its LSD-based drug ...
Definium Therapeutics (NASDAQ: DFTX) is set to present findings from three positive Phase 3 clinical trials of its LSD-based drug ...
The Nasdaq-listed psychedelic medicine developer will participate in four major healthcare conferences during November and December as it prepares for ...
Psychedelics.media delivers trusted news, intelligence, and insights for the global psychedelic medicine industry.
